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Human immunodeficiency virus type 1
(HIV-1) is a chronically replicating lenti-
virus that must escape from adaptive
immune responses that arise during the
course of infection. Viral persistence is
maintained by the rapid rate of HIV-1
replication and the error-prone reverse
transcription of the viral genome, which
produces viral variants that continually
escape antibody and cytotoxic T cell
responses [1–3]. Antibodies directed
against the gp120 and gp41 components
of the viral envelope glycoprotein (Env)
develop within the first few weeks of
infection [4,5], but antibodies that can
neutralize the infecting virus (NAbs) are
usually not detected until more than 12
weeks after HIV-1 infection [6]. Thus, in
natural HIV-1 infection, NAbs are not
believed to play a major role in containing
the acute phase of HIV-1 replication.
However, several studies have shown that
once NAbs arise, they exert immune
selection pressure on the viral quasispecies
[7–14].
Viral escape from autologous NAbs was
first described in lentiviral infections of
several animal species [15–17]. For exam-
ple, the successive waves of viremia in
horses caused by equine infectious anemia
virus are thought to be due to the
sequential development of viral variants
that temporarily evade the host NAb
response. HIV-1 escape from autologous
NAbs was first described in the early 1990s
[18–20]. Subsequently, numerous re-
search groups showed that plasma anti-
bodies from a time point contemporane-
ous with viral isolation did not neutralize
the autologous virus, and that NAbs
against the isolated virus developed only
months later [7–14,21,22]. Thus, the NAb
response continually lags behind viral
replication. The initial studies of NAb
escape were limited by the inefficiency of
isolating replication competent HIV-1
from patient plasma or lymphocytes. The
more recently performed studies used
molecularly cloned Env-pseudoviruses to
more robustly study the plasma viral
quasispecies at sequential time points.
These data confirmed that, at any given
time point during the course of HIV-1
infection, the circulating quasispecies of
viral variants is resistant to the circulating
plasma NAb. At first glance, these findings
might suggest that HIV-1 should become
progressively more resistant to neutraliza-
tion over time. Interestingly, this is not the
case. HIV-1 isolates that are resistant to
circulating autologous NAbs generally
remain sensitive to neutralization by
several known monoclonal antibodies
(mAbs) or by heterologous plasma ob-
tained for other individuals with HIV-1.
This has led to several key questions
related to autologous virus NAb escape:
What are the Env epitopes targeted by
early autologous NAbs and how does the
virus escape from these NAbs? How does
continuous neutralization escape occur
without leading to global changes in viral
neutralization sensitivity? Finally, what are
the implications of NAb escape for HIV-1
vaccines?
In this issue of PLoS Pathogens, two teams
of investigators provide some initial an-
swers to these questions [23,24]. Both
groups utilized clinical samples collected
from seroconversion cohorts of individuals
with subtype C HIV-1. The investigators
studied the development of the autologous
NAb response from the acute phase,
though the first 2 years of infection. A
limiting dilution PCR methodology was
used to clone and study HIV-1 variants
from sequential plasma samples over time.
Moore and colleagues studied four indi-
viduals and found that the early NAb
response was restricted to two epitopes on
the HIV-1 Env. They used chimeric viral
clones and site-specific mutagenesis to
define an epitope composed of the first
and second variable region (V12) of the
HIV-1 Env. A second epitope was identi-
fied within a variable alpha-2 helix region
of Env that is just past the V3 loop. The
restricted nature of the autologous NAb
response to variable Env regions is an
important finding, because it helps to
explain how the virus can readily mutate
to evade the NAb response. The V12
region in particular can tolerate insertions
and deletions of amino acid residues
without sacrificing Env function. In addi-
tion, specific amino acid changes and
alterations in glycosylation in these two
epitopes were found to be associated with
neutralization escape. In one individual,
the development of a NAb response to the
alpha-2 helix region was associated with a
7-fold drop in plasma viremia, and a 4-fold
rebound as neutralization escape oc-
curred. Rong and colleagues similarly
studied longitudinal samples from two
individuals and found a highly restricted
set of NAbs. They also identified the V12
region as a key target of autologous NAbs.
Mapping studies demonstrated that spe-
cific amino acid sequence alterations, as
well as changes in the pattern of glycosyl-
ation, were important components of
neutralization escape. Importantly, they
were able to isolate two mAbs from one
patient, and demonstrated that a single
amino acid substitution affecting a glyco-
sylation site in V2 was responsible for
resistance to these mAbs. In some cases,
mutations outside of the specific neutral-
ization epitopes were also associated with
neutralizing escape. Given the complex
trimeric structure of the HIV-1 Env, it is
well known that distant mutations can
affect the conformational structure of Env
and impact antibody recognition of an
epitope [25]. While these two new studies
have probably not described the full
spectrum of autologous NAb responses,
the consistent finding of an early dominant
NAb response to one or two variable
regions of Env that can vary without major
cost to viral fitness does help explain how
the virus is able to effectively evade the
NAb response.
Citation: Mascola JR (2009) The Cat and Mouse of HIV-1 Antibody Escape. PLoS Pathog 5(9): e1000592.
doi:10.1371/journal.ppat.1000592
Editor: Kasturi Haldar, University of Notre Dame, United States of America
Published September 18, 2009
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration
which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: The author received no specific funding for this article.
Competing Interests: The author has declared that no competing interests exist.
* E-mail: jmascola@nih.gov
PLoS Pathogens | www.plospathogens.org 1 September 2009 | Volume 5 | Issue 9 | e1000592The study of the early autologous NAb
response adds to our understanding of the
role of NAbs in natural HIV-1 infection,
and has potential implications for HIV-1
vaccine design. We know that, over time,
more broadly reactive NAbs develop in
some individuals with HIV-1 [26–28].
These NAbs appear to target functionally
conserved regions of Env such as the
receptor or co-recpetor binding sites, or
conserved regions of gp41 [27,29–31].
Thus, immune escape from such NAbs
would, in theory, be much more difficult
[32]. In addition, these antibodies can
protect against AIDS virus infection in
non-human primate models [33,34]. We
still do not understand why such NAbs
arise so late during the course of HIV-1
infection. Hence, investigators should con-
tinue to study the longer-term evolution of
the NAb response in order to better
understand the early epitope dominance
of the autologous NAb response, and the
clinical and virologic factors associated
with the evolution from a type-restricted
NAb response to a more broadly reactive
response. While NAbs may arise too late
during natural HIV-1 infection to have a
major impact on HIV-1 replication, a
major goal of vaccine researchers is to
generate pre-existing NAb responses that
can prevent initial HIV-1 infection, or
contain the virus during the initial phase of
viral dissemination [3,26,35,36]. A better
understanding of the evolution of the
natural NAb response during natural
infection, including the viral epitopes
targeted, can provide insights for vaccine
immunogen design.
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